他汀类药物治疗在非肌肉侵入性膀胱癌患者中的潜在益处
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer
影响因子:4.40000
分区:医学2区 / 泌尿学与肾脏学2区
发表日期:2025 Jan
作者:
Kang Liu, Rossella Nicoletti, Hongda Zhao, Xuan Chen, Peter Ka-Fung Chiu, Chi-Fai Ng, Renate Pichler, Laura S Mertens, Takafumi Yanagisawa, Luca Afferi, Andrea Mari, Satoshi Katayama, Juan Gomez Rivas, Riccardo Campi, Maria Carmen Mir, Michael Rink, Yair Lotan, Morgan Rouprêt, Shahrokh F Shariat, Jeremy Yuen-Chun Teoh
摘要
研究他汀类药物对接受辅助术中的巴西氏菌（BCG）免疫疗法治疗的非肌肉侵入性膀胱癌（NMIBC）患者的生存结果的影响。一项对接受插入性BCG治疗的NMIBC连续患者的回顾性同类疗法。使用Kaplan-Meier方法和多变量COX回归分析了总体生存期（OS），癌症特异性生存（CSS），无复发生存（RFS）和无进展生存期（PFS）与NO-Statins组之间的分析。中位随访时间为11。0年。在Kaplan-Meier分析中，他汀类药物组具有明显的更好OS（P <0.001），CSS（P <0.001）和PFS（P <0.001）。亚组分析表明，汀类药物治疗在BCG治疗具有更好的CS（P = 0.02）和PFS（P <0.01）之前开始。在多变量的COX回归分析中，“ BCG”组之前的汀类药物是OS的独立保护因素（危险比[HR] 0.607，95％置信区间[CI] 0.514-0.716）和CSS和CSS（HR 0.571，95％CI 0.376-0.868），但95％CI 0.376-0.868）（HR）（HR）（HR 0.376-0.868）（HR R.888888888888） 0.736-1.065）和PFS（HR 0.689，95％CI 0.469-1.013）.STATINS治疗似乎对接受NMIBC接受辅助术静脉内BCG患者的OS和CSS具有保护作用。
Abstract
To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guérin (BCG) immunotherapy.A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression.A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013).Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG.